FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Elihu Estey

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Activities & Behaviors

Clinical Trials, Phase II as Topic

Co-author Network

Publications

TOP 3
Mazyar Shadman; Elihu H Estey
Prophylactic use of granulocyte colony-stimulating factor after consolidation therapy with high-dose cytarabine for acute myeloid leukemia.
Elihu H Estey
Acute myeloid leukemia: 2013 update on risk-stratification and management.
Roland B Walter; Frederick R Appelbaum; Alan K Burnett; Anna Evans; Robert K Hills; Hagop M Kantarjian; Bob Löwenberg; Gert J Ossenkoppele; Megan Othus; Sherry R Pierce; Farhad Ravandi; Kees G M van Montfort; Elihu H Estey
Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Elihu Estey (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Mazyar Shadman; Elihu H Estey
Prophylactic use of granulocyte colony-stimulating factor after consolidation therapy with high-dose cytarabine for acute myeloid leukemia.
Expert review of hematology 2013;6(2):131-3.
2013: Elihu H Estey
Acute myeloid leukemia: 2013 update on risk-stratification and management.
American journal of hematology 2013;88(4):318-27.
2013: Roland B Walter; Frederick R Appelbaum; Alan K Burnett; Anna Evans; Robert K Hills; Hagop M Kantarjian; Bob Löwenberg; Gert J Ossenkoppele; Megan Othus; Sherry R Pierce; Farhad Ravandi; Kees G M van Montfort; Elihu H Estey
Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients.
Blood 2013;121(13):2424-31.
2013: Pamela S Becker; Frederick R Appelbaum; Stephan Faderl; Hagop M Kantarjian; Sherry Pierce; Jianqin Shan; Barry Storer; Elihu H Estey
Retrospective comparison of clofarabine versus fludarabine in combination with high-dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia.
Haematologica 2013;98(1):114-8.
2012: Farhad Ravandi; Charles Alan Schiffer; Richard A Larson; Francesco Lo Coco; Frederick R Appelbaum; Alan K Burnett; Elihu H Estey; Hagop M Kantarjian
Gemtuzumab ozogamicin: time to resurrect?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(32):3921-3.
2012: Judith E Karp; Mark Levis; Karen Mackey; A MICHAEL MCDEVITT; Megan Othus; Keith William Pratz; MICHELLE RUDEK-RENAUT; Margaret Mary Showel; B Douglas Smith; John J Wright; Hetty Carraway; Kathleen Shannon Dorcy; L Austin Doyle; D Michelle Drye; Elihu H Estey; Elizabeth Garrett-Mayer; Douglas E Gladstone; Steven D Gore; Jacqueline M Greer; John M Pagel
Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.
Haematologica 2012;97(11):1736-42.
2012: Elihu H Estey
Intensity of conditioning for allogeneic haemopoetic cell transplantation.
The lancet oncology 2012;13(10):966-8.
2012: Raya Mawad; Elihu H Estey
Acute myeloid leukemia with normal cytogenetics.
Current oncology reports 2012;14(5):359-68.
2012: Bruno C Medeiros; Megan Othus; Elihu H Estey; Min Fang; Frederick R Appelbaum
Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia.
Haematologica 2012;97(9):1401-4.
2012: Aaron T Gerds; Ted A Gooley; Frederick R Appelbaum; H Joachim Deeg; Elihu H Estey; Bart L Scott
Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2012;18(8):1211-8.
2012: Rajeev Rajendra; Elihu H Estey
Management of acute promyelocytic leukemia: implications for treatment of other cancers.
Oncology (Williston Park, N.Y.) 2012;26(7):641, 646-7.
2012: Roland B Walter; Elihu H Estey; Frederick R Appelbaum; Irwin D Bernstein
Acute myeloid leukemia stem cells and CD33-targeted immunotherapy.
Blood 2012;119(26):6198-208.
2012: Roland B Walter; Frederick R Appelbaum; Bruno C Medeiros; Bayard L Powell; Charles Alan Schiffer; Elihu H Estey
Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia.
Haematologica 2012;97(5):739-42.
2012: Bruno C Medeiros; Megan Othus; Frederick R Appelbaum; Min Fang; Elihu H Estey
Impact of residual normal metaphases in core binding factor acute myeloid leukemia.
Cancer 2012;118(9):2420-3.
2011: Roland B Walter; Frederick R Appelbaum; Gautam Borthakur; Jorge E Cortes; Hagop A Kantarjian; Megan Othus; Sherry A Pierce; Farhad Ravandi; Elihu H Estey
Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(33):4417-23.
2011: Pamela S Becker; Frederick R Appelbaum; Stephan Faderl; Elizabeth Harrington; Paul C Hendrie; Hagop M Kantarjian; John M Pagel; Stephen H Petersdorf; Sherry Pierce; Jianqin Shan; Andrei R Shustov; Derek L Stirewalt; Barry Storer; Elihu H Estey
Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia.
British journal of haematology 2011;155(2):182-9.
2011: Elihu H Estey; Fred Hutchinson
Newly diagnosed acute promyelocytic leukemia: arsenic moves front and center.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(20):2743-6.
2011: Elihu H Estey
Treatment of acute myeloid leukemia in the elderly.
Haematologica 2011;96(6):795-8.
2011: Roland B Walter; Stephanie J Lee; Kelda M Gardner; Xiaoyu Chai; Kathleen Shannon Dorcy; Frederick R Appelbaum; Elihu H Estey
Outpatient management following intensive induction chemotherapy for myelodysplastic syndromes and acute myeloid leukemia: a pilot study.
Haematologica 2011;96(6):914-7.
2011: Bin Xie; Megan Othus; Bruno C Medeiros; Min Fang; Frederick R Appelbaum; Elihu H Estey
Influence of residual normal metaphases in acute myeloid leukemia patients with monosomal karyotype.
Haematologica 2011;96(4):631-2.
2011: Roland B Walter; Theodore A Gooley; Brent L Wood; Filippo Milano; Min Fang; Mohamed L Sorror; Elihu H Estey; Alexander I Salter; Emily Lansverk; Jason W Chien; Ajay K Gopal; Frederick R Appelbaum; John M Pagel
Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(9):1190-7.
2010: Roland B Walter; Frederick R Appelbaum; Martin S Tallman; Noel S Weiss; Richard A Larson; Elihu H Estey
Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.
Blood 2010;116(14):2420-8.
2010: Roland B Walter; Hagop M Kantarjian; Xuelin Huang; Sherry A Pierce; Zhuoxin Sun; Holly M Gundacker; Farhad Ravandi; Stefan H Faderl; Martin S Tallman; Frederick R Appelbaum; Elihu H Estey
Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(10):1766-71.
2010: Bart L Scott; Aravind Ramakrishnan; Barry Storer; Pamela S Becker; Steve Petersdorf; Elihu H Estey; H Joachim Deeg
Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept.
British journal of haematology 2010;148(6):944-7.
2010: Hartmut Döhner; Elihu H Estey; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Alan K Burnett; Hervé Dombret; Pierre Fenaux; David Grimwade; Richard A Larson; Francesco Lo Coco; Tomoki Naoe; Dietger Niederwieser; Gert Ossenkoppele; MA Sanz; Jorge Sierra; Martin S Tallman; Bob Löwenberg; Clara D Bloomfield
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.
Blood 2010;115(3):453-74.
2009: Cameron J Turtle; Hillary M Swanson; Nobuharu Fujii; Elihu H Estey; Stanley R Riddell
A distinct subset of self-renewing human memory CD8+ T cells survives cytotoxic chemotherapy.
Immunity 2009;31(5):834-44.
2009: Aaron D Schimmer; Elihu H Estey; Gautam Borthakur; Bing Z Carter; Gary J Schiller; Martin S Tallman; Jessica K Altman; Judith E Karp; Jeannine Kassis; David W Hedley; Joseph Brandwein; Wei Xu; Duncan H Mak; Eric LaCasse; Christine Jacob; Stephen J Morris; Jacques Jolivet; Michael Andreeff
Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4741-6.
2009: S Heinrichs; R V Kulkarni; C E Bueso-Ramos; Ross Levine; Mignon L Loh; Cheng Li; Donna Neuberg; Steven M Kornblau; Jean-Pierre J Issa; D Gary Gilliland; G Garcia-Manero; H M Kantarjian; Elihu H Estey; A Thomas Look
Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics.
Leukemia 2009;23(9):1605-13.
2009: Maher Albitar; Steven Potts; Francis Giles; Susan O'Brien; Iman Jilani; Amber C Donahue; Elihu H Estey; Andrew Lamb
Proteomics-based prediction of clinical response in acute myeloid leukemia.
Experimental hematology 2009;37(7):784-90.
2009: Zhihong Zeng; Yue-Xi Shi; Ismael Samudio; Rui-Yu Wang; Xiaoyang Ling; Olga Frolova; Mark Levis; Joshua B Rubin; Robert R Negrin; Elihu H Estey; Sergej Konoplev; Michael Andreeff; Marina Konopleva
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.
Blood 2009;113(24):6215-24.
2009: Elihu H Estey
Incorporating novel treatment strategies into conventional therapy.
Clinical advances in hematology & oncology : H&O 2009;7(6):4-7.
2009: Roland B Walter; Elihu H Estey
The power of comparative studies.
Leukemia research 2009;33(5):610-2.
2009: Miguel A Sanz; David Grimwade; Martin S Tallman; Bob Lowenberg; Pierre Fenaux; Elihu H Estey; Tomoki Naoe; Eva Lengfelder; Thomas Büchner; Hartmut Döhner; Alan K Burnett; Francesco Lo Coco
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
Blood 2009;113(9):1875-91.
2009: Rodrigo T Calado; Joshua A Regal; Mark Hills; William T Yewdell; Leandro F Dalmazzo; Marco Zago; Peter M Lansdorp; Donna Hogge; STEPHEN CHANOCK; Elihu H Estey; Roberto P Falcão; Neal S Young
Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(4):1187-92.
2009: Elihu H Estey
Treatment of acute myeloid leukemia.
Haematologica 2009;94(1):10-6.
2008: Gautam Borthakur; Andrew Lamb; Xuemei Wang; William Plunkett; Varsha Gandhi; Stefan Faderl; Guillermo Garcia-Manero; Farhad Ravandi; Sherry Pierce; Elihu H Estey
Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.
Cancer 2008;113(11):3181-5.
2008: Peter F Thall; Hoang Q Nguyen; Elihu H Estey
Patient-specific dose finding based on bivariate outcomes and covariates.
Biometrics 2008;64(4):1126-36.
2008: J Kyle Wathen; Peter F Thall; John D Cook; Elihu H Estey
Accounting for patient heterogeneity in phase II clinical trials.
Statistics in medicine 2008;27(15):2802-15.
2008: Elihu H Estey
Older adults: should the paradigm shift from standard therapy?
Best practice & research. Clinical haematology 2008;21(1):61-6.
2008: Apostolia-Maria Tsimberidou; Hagop M Kantarjian; Sijin Wen; Susan O'Brien; Jorge Cortes; William G Wierda; Charles Koller; Sherry Pierce; Mark Brandt; Emil J Freireich; Michael J Keating; Elihu H Estey
The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(3):721-30.
2008: Razelle Kurzrock; Hagop M Kantarjian; Michelle A Blascovich; Cindy Bucher; Srdan Verstovsek; John J Wright; Susan R Pilat; Jorge E Cortes; Elihu H Estey; Francis Giles; Miloslav Beran; Said M Sebti
Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(2):509-14.
2008: Sara S Strom; Vivianne Vélez-Bravo; Elihu H Estey
Epidemiology of myelodysplastic syndromes.
Seminars in hematology 2008;45(1):8-13.
2007: Andres O Soriano; Hui Yang; Stefan Faderl; Zeev Estrov; Francis Giles; Farhad Ravandi; Jorge Cortes; William G Wierda; Souzanne Ouzounian; Andres Quezada; Sherry Pierce; Elihu H Estey; Jean-Pierre J Issa; Hagop M Kantarjian; Guillermo Garcia-Manero
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Blood 2007;110(7):2302-8.
2007: Xiaoping Sun; Wei Zhang; Latha Ramdas; David N Stivers; Daniel M Jones; Hagop M Kantarjian; Elihu H Estey; Saroj Vadhan-Raj; L Jeffrey Medeiros; Carlos E Bueso-Ramos
Comparative analysis of genes regulated in acute myelomonocytic leukemia with and without inv(16)(p13q22) using microarray techniques, real-time PCR, immunohistochemistry, and flow cytometry immunophenotyping.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2007;20(8):811-20.
2007: Ahmed Aribi; Hagop M Kantarjian; Elihu H Estey; Charles Koller; Deborah A Thomas; Steven M Kornblau; Stefan Faderl; Nakia M Laddie; Guillermo Garcia-Manero; Jorge E Cortes
Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia.
Cancer 2007;109(7):1355-9.
2007: Elihu H Estey
Advances in the management of AML in the elderly.
Clinical advances in hematology & oncology : H&O 2007;5(3):185-7.
2006: Frederick R Appelbaum; Kenneth J Kopecky; Martin S Tallman; Marilyn L Slovak; Holly Gundacker; Haesook T Kim; Gordon W Dewald; Hagop M Kantarjian; Sherry R Pierce; Elihu H Estey
The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations.
British journal of haematology 2006;135(2):165-73.
2006: Steven M Kornblau; Matthew Womble; Yi Hua Qiu; C Ellen Jackson; Wenjing Chen; Marina Konopleva; Elihu H Estey; Michael Andreeff
Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia.
Blood 2006;108(7):2358-65.
2006: Wolfgang Kern; Elihu H Estey
High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials.
Cancer 2006;107(1):116-24.
2006: Elihu H Estey
General approach to, and perspectives on clinical research in, older patients with newly diagnosed acute myeloid leukemia.
Seminars in hematology 2006;43(2):89-95.
2006: Peter F Thall; Elihu H Estey; Maurie Markman
Some ethical issues in phase II trials in acute leukemia.
Clinical advances in hematology & oncology : H&O 2006;4(2):95.
2006: Xuelin Huang; Swati Biswas; Elihu H Estey; Donald A Berry
Building and validating a prognostic index for biomarker studies.
Cancer biomarkers : section A of Disease markers 2006;2(3-4):97-101.
2006: Peter F Thall; John D Cook; Elihu H Estey
Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations.
Journal of biopharmaceutical statistics 2006;16(5):623-38.
2006: Gloria N Mattiuzzi; Gladys Alvarado; Francis Giles; Luis Ostrosky-Zeichner; Jorge Cortes; Susan O'Brien; Srdan Verstovsek; Stefan Faderl; Xian Zhou; Issam I Raad; B Nebiyou Bekele; Gerhard J Leitz; Ivonne Lopez-Roman; Elihu H Estey
Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies.
Antimicrobial agents and chemotherapy 2006;50(1):143-7.
2005: Peter F Thall; Elihu H Estey
Some ethical issues in phase II trials in acute leukemia.
Clinical advances in hematology & oncology : H&O 2005;3(12):943-8.
2005: Sara S Strom; Y Gu; S K Gruschkus; Sherry A Pierce; Elihu H Estey
Risk factors of myelodysplastic syndromes: a case-control study.
Leukemia 2005;19(11):1912-8.
2005: Richard A Larson; Eric L Sievers; Edward A Stadtmauer; Bob Löwenberg; Elihu H Estey; Hervé Dombret; Matthias Theobald; Dimitris Voliotis; John M Bennett; Maria Richie; Lance H Leopold; Mark S Berger; Matthew L Sherman; Michael R Loken; Jacques J M van Dongen; Irwin D Bernstein; Frederick R Appelbaum
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.
Cancer 2005;104(7):1442-52.
2005: Hesham M Amin; Y Yang; Yu Shen; Elihu H Estey; Francis Giles; Sherry A Pierce; Hagop M Kantarjian; Susan M O'Brien; Iman Jilani; Maher Albitar
Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias.
Leukemia 2005;19(9):1567-72.
2005: Stefan Heinrichs; Jason N Berman; Taylor M Ortiz; Steven M Kornblau; Donna Neuberg; Elihu H Estey; A Thomas Look
CD34+ cell selection is required to assess HOXA9 expression levels in patients with myelodysplastic syndrome.
British journal of haematology 2005;130(1):83-6.
2005: Chitra Hosing; Rima M Saliba; Munir Shahjahan; Elihu H Estey; Daniel Couriel; Sergio Giralt; Borje Andersson; Richard E Champlin; Marcos De Lima
Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia.
Bone marrow transplantation 2005;36(2):157-62.
2005: Mignon L Loh; Simone Martinelli; Viviana Cordeddu; Melissa G Reynolds; Shashaank Vattikuti; Connie M Lee; Michael Wulfert; Ulrich Germing; Peter Haas; Charlotte Niemeyer; Miloslav E Beran; Sara Strom; Michael Lübbert; Mariella Sorcini; Elihu H Estey; Norbert Gattermann; Marco Tartaglia
Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Leukemia research 2005;29(4):459-62.
2005: Elihu H Estey
"3+7" therapy for the treatment of acute myeloid leukemia. CON.
Clinical advances in hematology & oncology : H&O 2005;3(2):129-132, 141.
2004: Elihu H Estey
Modulation of angiogenesis in patients with myelodysplastic syndrome.
Best practice & research. Clinical haematology 2004;17(4):623-39.
2004: Qinglong Hu; Amanda L Dey; Ying Yang; Yu Shen; Iman Jilani; Elihu H Estey; Hagop M Kantarjian; Francis Giles; Maher Albitar
Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes.
Cancer 2004;100(9):1884-91.
2004: Razelle Kurzrock; Maher Albitar; Jorge E Cortes; Elihu H Estey; Stefan Faderl; Guillermo Garcia-Manero; Deborah A Thomas; Francis Giles; Mary Ellen Ryback; Alain Thibault; P De Porre; Hagop M Kantarjian
Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(7):1287-92.
2004: Pei Lin; Suyang Hao; L Jeffrey Medeiros; Elihu H Estey; Sherry A Pierce; Xuemei Wang; Armand B. Glassman; Carlos E Bueso-Ramos; Yang O Huh
Expression of CD2 in acute promyelocytic leukemia correlates with short form of PML-RARalpha transcripts and poorer prognosis.
American journal of clinical pathology 2004;121(3):402-7.
2004: Yoko Tabe; Marina Konopleva; Mark F Munsell; Frank C Marini; Claudia Zompetta; Teresa McQueen; Twee Tsao; Shourong Zhao; Sherry Pierce; Jun Igari; Elihu H Estey; Michael Andreeff
PML-RARalpha is associated with leptin-receptor induction: the role of mesenchymal stem cell-derived adipocytes in APL cell survival.
Blood 2004;103(5):1815-22.
2003: Bruce D Cheson; John M Bennett; Kenneth J Kopecky; Thomas Büchner; Cheryl L Willman; Elihu H Estey; Charles Alan Schiffer; Hartmut Doehner; Martin S Tallman; T Andrew Lister; Francesco Lo Coco; Rein Willemze; Andrea Biondi; Wolfgang Hiddemann; Richard A Larson; Bob Löwenberg; Miguel A Sanz; David R Head; Ryuzo Ohno; Clara D Bloomfield; Francesco LoCocco
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(24):4642-9.
2003: Salim Yazji; Francis Giles; Apostolia-Maria Tsimberidou; Elihu H Estey; Hagop M Kantarjian; S A O'Brien; Razelle Kurzrock
Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes.
Leukemia 2003;17(11):2101-6.
2003: Elihu H Estey; Peter F Thall; Xuemei Wang; Srdan Verstovsek; Jorge Cortes; Hagop M Kantarjian
Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML.
Blood 2003;102(9):3097-9.
2003: Barry D Hock; Judith L McKenzie; William Nigel Patton; Lisa F Haring; Ying Yang; Yu Shen; Elihu H Estey; Maher Albitar
The clinical significance of soluble CD86 levels in patients with acute myeloid leukemia and myelodysplastic syndrome.
Cancer 2003;98(8):1681-8.
2003: Raymond Wong; Sergio Giralt; Thomas Martin; Daniel Couriel; Athanasios Anagnostopoulos; Chitra Hosing; Borje S Andersson; Pedro Cano; Munir Shahjahan; Cindy Ippoliti; Elihu H Estey; John McMannis; James L Gajewski; Richard E Champlin; Marcos De Lima
Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.
Blood 2003;102(8):3052-9.
2003: Elihu H Estey
Treatment options for relapsed acute promyelocytic leukaemia.
Best practice & research. Clinical haematology 2003;16(3):521-34.
2003: Francis Giles; Jorge E Cortes; Terri A Halliburton; Susie J Mallard; Elihu H Estey; Tracey A Waddelow; JoAnn T Lim
Intravenous corticosteroids to reduce gemtuzumab ozogamicin infusion reactions.
The Annals of pharmacotherapy 2003;37(9):1182-5.
2003: Elihu H Estey
Adaptive randomization in a treatment study of patients with adverse karyotype acute myeloid leukemia.
Current oncology reports 2003;5(5):390.
2003: Elihu H Estey
Early blast clearance by remission induction as a prognostic factor in acute myeloid leukemia.
Current oncology reports 2003;5(5):389.
2003: Simona Gatto; Greg Ball; Francesco Onida; Hagop M Kantarjian; Elihu H Estey; Miloslav Beran
Contribution of beta-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS).
Blood 2003;102(5):1622-5.
2003: Hesham M Amin; Iman Jilani; Elihu H Estey; Michael J Keating; Amanda L Dey; Taghi Manshouri; Hagop M Kantarjian; Zeev Estrov; Jorge E Cortes; Deborah A Thomas; Francis Giles; Maher Albitar
Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome.
Blood 2003;102(5):1866-8.
2003: Elihu H Estey; Peter F Thall
New designs for phase 2 clinical trials.
Blood 2003;102(2):442-8.
2003: Marina Konopleva; Su-Chun Cheng; Jorge E Cortes; Kimberly J Hayes; Sherry A Pierce; Michael Andreeff; Francis Giles; Susan O'Brien; Hagop M Kantarjian; Elihu H Estey
Independent prognostic significance of day 21 cytogenetic findings in newly-diagnosed acute myeloid leukemia or refractory anemia with excess blasts.
Haematologica 2003;88(7):733-6.
2003: Francis Giles; Hagop M Kantarjian; Jorge E Cortes; Guillermo Garcia-Manero; Srdan Verstovsek; Stefan Faderl; Deborah A Thomas; Alessandra Ferrajoli; Susan O'Brien; J Kyle Wathen; Lian-Chun Xiao; Donald A Berry; Elihu H Estey
Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(9):1722-7.
2003: Lance H Leopold; Mark S Berger; Su-Chun Cheng; Jorge E Cortes-Franco; Francis Giles; Elihu H Estey
Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse.
Clinical advances in hematology & oncology : H&O 2003;1(4):220-5.
2003: Francis Giles; Stefan Faderl; Deborah A Thomas; Jorge E Cortes; Guillermo Garcia-Manero; Dan Douer; Alexandra M Levine; Charles Koller; Sima Jeha; Susan M O'Brien; Elihu H Estey; Hagop M Kantarjian
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(6):1050-6.
2003: Elihu H Estey
Current challenges in therapy of myelodysplastic syndromes.
Current opinion in hematology 2003;10(1):60-7.
2002: Alvaro Aguayo; Hagop M Kantarjian; Elihu H Estey; Francis Giles; Srdan Verstovsek; Taghi Manshouri; Christy Gidel; Susan O'Brien; Michael J Keating; Maher Albitar
Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes.
Cancer 2002;95(9):1923-30.
2002: Christina A Meyers; Lee F Seabrooke; Maher Albitar; Elihu H Estey
Association of cancer-related symptoms with physiological parameters.
Journal of pain and symptom management 2002;24(4):359-61.
2002: Maher Albitar; Taghi Manshouri; Yu Shen; Diane Liu; Miloslav Beran; Hagop M Kantarjian; Anna Rogers; Iman Jilani; Chung-Wu Lin; Sherry Pierce; Emil J Freireich; Elihu H Estey
Myelodysplastic syndrome is not merely "preleukemia".
Blood 2002;100(3):791-8.
2002: Elihu H Estey; Peter F Thall; Francis Giles; Xue-Mei Wang; Jorge E Cortes; Miloslav Beran; Sherry A Pierce; Deborah A Thomas; Hagop M Kantarjian
Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside.
Blood 2002;99(12):4343-9.
2002: Elihu H Estey; Francis Giles; Miloslav Beran; Susan O'Brien; Sherry A Pierce; Stefan Faderl; Jorge E Cortes; Hagop M Kantarjian
Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia.
Blood 2002;99(11):4222-4.
2002: Elihu H Estey
Treatment of acute myelogenous leukemia.
Oncology (Williston Park, N.Y.) 2002;16(3):343-52, 355-6; discussion 357, 362, 365-6.
2002: Elihu H Estey
New drugs for therapy of AML.
Leukemia 2002;16(3):306-9.
2002: Varsha Gandhi; William Plunkett; Min Du; Mary Ayres; Elihu H Estey
Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(3):665-73.
2002: Francesco Onida; Hagop M Kantarjian; Terry L Smith; Greg Ball; Michael J Keating; Elihu H Estey; Armand B. Glassman; Maher Albitar; Monica Kwari; Miloslav Beran
Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients.
Blood 2002;99(3):840-9.
2001: Elihu H Estey; Peter F Thall; Jorge E Cortes; Francis Giles; Susan O'Brien; Sherry A Pierce; Xuemei Wang; Hagop M Kantarjian; Miloslav Beran
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts.
Blood 2001;98(13):3575-83.
2001: Miloslav Beran; Yu Shen; Andrew Lamb; Susan O'Brien; Charles Koller; Francis Giles; Jorge Cortes; Deborah A Thomas; Stefan Faderl; Simona Despa; Elihu H Estey
High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens.
Cancer 2001;92(8):1999-2015.
2001: Elihu H Estey
Therapeutic options for acute myelogenous leukemia.
Cancer 2001;92(5):1059-73.
2001: Samer Bibawi; D Abi-Said; Luis Fayad; Paolo Anderlini; Naoto T Ueno; RC Mehra; Issa Khouri; Sergio Giralt; James L Gajewski; Michele Donato; David F Claxton; Ira Braunschweig; Koen van Besien; Michael Andreeff; Borje S Andersson; Elihu H Estey; Richard Champlin; Donna Przepiorka
Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.
American journal of hematology 2001;67(4):227-33.
2001: Francis Giles; Hagop M Kantarjian; Steven M Kornblau; Deborah A Thomas; Guillermo Garcia-Manero; Tracey A Waddelow; Cynthia L David; Alexandria Phan; Dawn E Colburn; Asif Rashid; Elihu H Estey
Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation.
Cancer 2001;92(2):406-13.
2001: Elihu H Estey
Prognostic factors in acute myelogenous leukemia.
Leukemia 2001;15(4):670-2.
2001: Elihu H Estey
Growth factors in acute myeloid leukaemia.
Best practice & research. Clinical haematology 2001;14(1):175-87.
2000: S Ibrahim; Elihu H Estey; Sherry Pierce; Armand B. Glassman; Michael Keating; Susan O'Brien; Hagop M Kantarjian; Maher Albitar
11q23 abnormalities in patients with acute myelogenous leukemia and myelodysplastic syndrome as detected by molecular and cytogenetic analyses.
American journal of clinical pathology 2000;114(5):793-7.
2000: Elihu H Estey
How I treat older patients with AML.
Blood 2000;96(5):1670-3.
2000: Elihu H Estey
Treatment of relapsed and refractory acute myelogenous leukemia.
Leukemia 2000;14(3):476-9.
2000: Elihu H Estey; Sherry Pierce; Michael J Keating
Identification of a group of AML/MDS patients with a relatively favorable prognosis who have chromosome 5 and/or 7 abnormalities.
Haematologica 2000;85(3):246-9.
2000: Elihu H Estey; Yu Shen; Peter F Thall
Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB.
Blood 2000;95(1):72-7.
1999: Michael Andreeff; Shuwei Jiang; Xin Zhang; Marina Konopleva; Zeev Estrov; Virginia Snell; Z Xie; M Fatih Okcu; G Sanchez-Williams; J Dong; Elihu H Estey; R C Champlin; Steven M Kornblau; John C Reed; Shourong Zhao
Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid.
Leukemia 1999;13(11):1881-92.
1999: Zeev Estrov; S K Manna; David Harris; Quin Van; Elihu H Estey; Hagop M Kantarjian; Moshe Talpaz; Bharat B Aggarwal
Phenylarsine oxide blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells.
Blood 1999;94(8):2844-53.
1999: Elihu H Estey; Francis Giles; Andrew Lamb; Susan O'Brien; Jorge Cortes; Emil J Freireich; Gabriel Lopez-Berestein; Michael Keating
Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia.
Blood 1999;94(7):2230-5.
1999: R Aboul-Nasr; Elihu H Estey; Hagop M Kantarjian; Emil J Freireich; Michael Andreeff; B J Johnson; Maher Albitar
Comparison of touch imprints with aspirate smears for evaluating bone marrow specimens.
American journal of clinical pathology 1999;111(6):753-8.
1999: R Weinkauff; Elihu H Estey; P Starostik; Kimberly Hayes; Yang O Huh; Cheryl Hirsch-Ginsberg; Michael Andreeff; Michael Keating; Hagop M Kantarjian; Emil J Freireich; Maher Albitar
Use of peripheral blood blasts vs bone marrow blasts for diagnosis of acute leukemia.
American journal of clinical pathology 1999;111(6):733-40.
1999: Peter F Thall; J Jack Lee; C H Tseng; Elihu H Estey
Accrual strategies for phase I trials with delayed patient outcome.
Statistics in medicine 1999;18(10):1155-69.
1999: Elihu H Estey; Peter F Thall; Sherry Pierce; Jorge Cortes; Miloslav Beran; Andrew Lamb; Michael J Keating; Michael Andreeff; Emil J Freireich
Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
Blood 1999;93(8):2478-84.
1999: Jorge E Cortes; Hagop M Kantarjian; Susan O'Brien; Francis Giles; Michael J Keating; Emil J Freireich; Elihu H Estey
A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission.
Cancer 1999;85(7):1506-13.
1999: Marina Konopleva; AA Mikhail; Zeev Estrov; Shourong Zhao; D Harris; G Sanchez-Williams; Steven M Kornblau; J Dong; K O Kliche; S Jiang; H R Snodgrass; Elihu H Estey; Michael Andreeff
Expression and function of leptin receptor isoforms in myeloid leukemia and myelodysplastic syndromes: proliferative and anti-apoptotic activities.
Blood 1999;93(5):1668-76.
1999: Peter F Thall; Elihu H Estey; Hsi-Guang Sung
A new statistical method for dose-finding based on efficacy and toxicity in early phase clinical trials.
Investigational new drugs 1999;17(2):155-67.
1998: Elihu H Estey
Incorporating new modalities into guidelines. Topotecan for myelodysplastic syndromes.
Oncology (Williston Park, N.Y.) 1998;12(11A):81-6.
1998: Zeev Estrov; Peter F Thall; Moshe Talpaz; Elihu H Estey; Hagop M Kantarjian; Michael Andreeff; David Harris; Quin Van; M Walterscheid; Steven M Kornblau
Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia.
Blood 1998;92(9):3090-7.
1998: Elihu H Estey
New agents for the treatment of acute myelogenous leukemia: focus on topotecan and retinoids.
Leukemia 1998;12 Suppl 1():S13-5.
1998: Alessandra Ferrajoli; Moshe Talpaz; Razelle Kurzrock; David Harris; Quin Van; Elihu H Estey; Zeev Estrov
Thrombopoietin stimulates myelodysplastic syndrome granulocyte-macrophage and erythroid progenitor proliferation.
Leukemia & lymphoma 1998;30(3-4):279-92.
1998: Elihu H Estey
Prognosis and therapy of secondary myelodysplastic syndromes.
Haematologica 1998;83(6):543-9.
1997: S Peleg; H Qiu; S Reddy; David Harris; Quin Van; Elihu H Estey; Moshe Talpaz; Zeev Estrov
1,25-Dihydroxyvitamin D3 and its analogues inhibit acute myelogenous leukemia progenitor proliferation by suppressing interleukin-1beta production.
The Journal of clinical investigation 1997;100(7):1716-24.
1996: H M Ghaddar; Sherry Pierce; Hagop M Kantarjian; Emil J Freireich; Michael J Keating; Elihu H Estey
Amsacrine and continuous-infusion high-dose cytosine arabinoside as induction therapy for patients with newly-diagnosed acute myelogenous leukemia.
Leukemia & lymphoma 1996;22(1-2):71-6.
1996: Paolo Anderlini; H M Ghaddar; Terry L Smith; Sherry Pierce; Hagop M Kantarjian; Susan O'Brien; Michael J Keating; Emil J Freireich; Elihu H Estey
Factors predicting complete remission and subsequent disease-free survival after a second course of induction therapy in patients with acute myelogenous leukemia resistant to the first.
Leukemia 1996;10(6):964-9.
1996: Varsha Gandhi; Elihu H Estey; Michael J Keating; William Plunkett
Intracellular pharmacodynamics in leukemia therapy.
[Rinshō ketsueki] The Japanese journal of clinical hematology 1996;37(5):369-79.
1996: Hagop M Kantarjian; Elihu H Estey; M A Keating
New chemotherapeutic agents in acute myeloid leukemia.
Leukemia 1996;10 Suppl 1():S4-6.
1996: Paolo Anderlini; Mario Luna; Hagop M Kantarjian; Susan O'Brien; Sherry Pierce; Michael J Keating; Elihu H Estey
Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes.
Leukemia 1996;10(4):600-8.
1996: S M Escudier; Hagop M Kantarjian; Elihu H Estey
Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid.
Leukemia & lymphoma 1996;20(5-6):435-9.
1996: Peter F Thall; R M Simon; Elihu H Estey
New statistical strategy for monitoring safety and efficacy in single-arm clinical trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(1):296-303.
1995: Zeev Estrov; Roy A Black; P R Sleath; David Harris; Quin Van; Ruth Lapushin; Elihu H Estey; Moshe Talpaz
Effect of interleukin-1 beta converting enzyme inhibitor on acute myelogenous leukemia progenitor proliferation.
Blood 1995;86(12):4594-602.
1995: Zeev Estrov; Moshe Talpaz; Elihu H Estey; G Strassmann
Role of suramin as an IL-1 inhibitor in suppression of acute myelogenous leukemia progenitor proliferation.
Experimental hematology 1995;23(10):1080-7.
1995: J F Seymour; Elihu H Estey; M J Keating; Razelle Kurzrock
Response to interferon-alpha in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine.
Leukemia 1995;9(5):929-32.
1995: H M Ghaddar; Sherry Pierce; P Reed; Elihu H Estey
Prognostic value of residual normal metaphases in acute myelogenous leukemia patients presenting with abnormal karyotype.
Leukemia 1995;9(5):779-82.
1995: Elihu H Estey; Hagop M Kantarjian; Susan O'Brien; Steven M Kornblau; Michael Andreeff; Miloslav Beran; Sherry Pierce; Michael Keating
High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
Cytokines and molecular therapy 1995;1(1):21-8.
1995: J F Seymour; Elihu H Estey
The contribution of Auer rods to the classification and prognosis of myelodysplastic syndromes.
Leukemia & lymphoma 1995;17(1-2):79-85.
1995: Peter F Thall; R M Simon; Elihu H Estey
Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes.
Statistics in medicine 1995;14(4):357-79.
1995: P Marlton; David F Claxton; P Liu; Elihu H Estey; Miloslav Beran; M LeBeau; J R Testa; Francis S Collins; J D Rowley; Michael J Siciliano
Molecular characterization of 16p deletions associated with inversion 16 defines the critical fusion for leukemogenesis.
Blood 1995;85(3):772-9.
1995: Lian Zhao; Kun-Sang Chang; Elihu H Estey; Kimberly Hayes; Albert Deisseroth; Jan C Liang
Detection of residual leukemic cells in patients with acute promyelocytic leukemia by the fluorescence in situ hybridization method: potential for predicting relapse.
Blood 1995;85(2):495-9.
1994: H M Ghaddar; Sanford A Stass; Sherry Pierce; Elihu H Estey
Cytogenetic evolution following the transformation of myelodysplastic syndrome to acute myelogenous leukemia: implications on the overlap between the two diseases.
Leukemia 1994;8(10):1649-53.
1994: Hagop M Kantarjian; Susan O'Brien; T Smith; Elihu H Estey; Miloslav Beran; Alejandro Preti; Sherry Pierce; Michael J Keating
Acute lymphocytic leukaemia in the elderly: characteristics and outcome with the vincristine-adriamycin-dexamethasone (VAD) regimen.
British journal of haematology 1994;88(1):94-100.
1994: H M Ghaddar; William Plunkett; Hagop M Kantarjian; Sherry Pierce; Emil J Freireich; Michael J Keating; Elihu H Estey
Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside.
Leukemia 1994;8(8):1269-74.
1994: J F Seymour; Razelle Kurzrock; Emil J Freireich; Elihu H Estey
2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia.
Blood 1994;83(10):2906-11.
1994: J F Seymour; S A Pierce; Hagop M Kantarjian; Michael J Keating; Elihu H Estey
Investigation of karyotypic, morphologic and clinical features in patients with acute myeloid leukemia blast cells expressing the neural cell adhesion molecule (CD56).
Leukemia 1994;8(5):823-6.
1994: F Maruyama; Sanford A Stass; Elihu H Estey; A Cork; M Hirano; T Ino; Emil J Freireich; P Yang; Kun-Sang Chang
Detection of AML1/ETO fusion transcript as a tool for diagnosing t(8;21) positive acute myelogenous leukemia.
Leukemia 1994;8(1):40-5.
1993: Elihu H Estey; Andrew Lamb; Michael Keating
Idarubicin plus continuous-infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrome.
Seminars in oncology 1993;20(6 Suppl 8):1-5.
1993: J F Seymour; Elihu H Estey
The prognostic significance of auer rods in myelodysplasia.
British journal of haematology 1993;85(1):67-76.
1993: Peter F Thall; Elihu H Estey
A Bayesian strategy for screening cancer treatments prior to phase II clinical evaluation.
Statistics in medicine 1993;12(13):1197-211.
1993: I A Jaiyesimi; Hagop M Kantarjian; Elihu H Estey
Advances in therapy for hairy cell leukemia. A review.
Cancer 1993;72(1):5-16.
1993: C L Reading; Elihu H Estey; Y O Huh; David F Claxton; G Sanchez; L W Terstappen; M C O'Brien; S Baron; Albert Deisseroth
Expression of unusual immunophenotype combinations in acute myelogenous leukemia.
Blood 1993;81(11):3083-90.
1993: Kun-Sang Chang; You-Hong Fan; Sanford A Stass; Elihu H Estey; G Wang; J M Trujillo; Paul F Erickson; Harry A Drabkin
Expression of AML1-ETO fusion transcripts and detection of minimal residual disease in t(8;21)-positive acute myeloid leukemia.
Oncogene 1993;8(4):983-8.
1993: Elihu H Estey; William Plunkett; Andrew Lamb; Mary Beth Rios; Michael J Keating
Treatment of relapsed or refractory AML with intermediate-dose arabinosylcytosine (ara-C): confirmation of the importance of ara-C triphosphate formation in mediating response to ara-C.
Leukemia & lymphoma 1993;10 Suppl():115-21.
1993: Elihu H Estey
Prognosis and therapy of myelodysplastic syndromes.
Cancer treatment and research 1993;64():233-67.
1992: Zeev Estrov; C H Park; C L Reading; Elihu H Estey; Moshe Talpaz; Razelle Kurzrock; Albert Deisseroth; Jordan U Gutterman
The effect of granulocyte-macrophage colony-stimulating factor on undifferentiated and mature acute myelogenous leukemia blast progenitors.
Experimental hematology 1992;20(7):886-90.
1992: Emil J Freireich; A Cork; Sanford A Stass; K B McCredie; Michael J Keating; Elihu H Estey; Hagop M Kantarjian; J M Trujillo
Cytogenetics for detection of minimal residual disease in acute myeloblastic leukemia.
Leukemia 1992;6(6):500-6.
1992: Zeev Estrov; Elihu H Estey; Michael Andreeff; Moshe Talpaz; Razelle Kurzrock; C L Reading; Albert Deisseroth; Jordan U Gutterman
Comparison of in vivo and in vitro effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with acute myeloid leukemia.
Experimental hematology 1992;20(5):558-64.
1992: Hagop M Kantarjian; Michael J Keating; Elihu H Estey; Susan O'Brien; Sherry Pierce; Miloslav Beran; Charles Koller; E Feldman; Moshe Talpaz
Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(5):772-8.
1992: Hagop M Kantarjian; Elihu H Estey; Susan O'Brien; E Anaissie; Miloslav Beran; Mary Beth Rios; Michael J Keating; Jordan U Gutterman
Intensive chemotherapy with mitoxantrone and high-dose cytosine arabinoside followed by granulocyte-macrophage colony-stimulating factor in the treatment of patients with acute lymphocytic leukemia.
Blood 1992;79(4):876-81.
1992: Elihu H Estey; Razelle Kurzrock; Hagop M Kantarjian; Susan M O'Brien; K B McCredie; Miloslav Beran; Charles Koller; Michael J Keating; Cheryl Hirsch-Ginsberg; Y O Huh
Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA).
Blood 1992;79(4):882-7.
1991: Hagop M Kantarjian; Moshe Talpaz; Michael J Keating; Elihu H Estey; Susan O'Brien; Miloslav Beran; K B McCredie; Jordan U Gutterman; Emil J Freireich
Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cancer 1991;68(6):1201-7.
1991: Razelle Kurzrock; Moshe Talpaz; J A Gomez; Elihu H Estey; Susan O'Brien; Cheryl Hirsch-Ginsberg; Charles Koller; Emil J Freireich; Jordan U Gutterman
Differential dose-related haematological effects of GM-CSF in pancytopenia: evidence supporting the advantage of low- over high-dose administration in selected patients.
British journal of haematology 1991;78(3):352-8.
1991: Elihu H Estey; Razelle Kurzrock; Moshe Talpaz; K B McCredie; Susan O'Brien; Hagop M Kantarjian; Michael J Keating; Albert Deisseroth; Jordan U Gutterman
Effects of low doses of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with myelodysplastic syndromes.
British journal of haematology 1991;77(3):291-5.
1990: Hagop M Kantarjian; Ronald S Walters; Michael J Keating; Terry L Smith; Susan O'Brien; Elihu H Estey; Y O Huh; J Spinolo; K Dicke; Bart Barlogie
Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(6):994-1004.
1990: Elihu H Estey; D Dixon; Hagop M Kantarjian; Michael J Keating; K McCredie; Gerald P Bodey; Razelle Kurzrock; Moshe Talpaz; Emil J Freireich; Albert Deisseroth
Treatment of poor-prognosis, newly diagnosed acute myeloid leukemia with ara-C and recombinant human granulocyte-macrophage colony-stimulating factor.
Blood 1990;75(9):1766-9.
1990: Elihu H Estey; Michael J Keating; K B McCredie; Emil J Freireich; William Plunkett
Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia.
Leukemia 1990;4(2):95-9.
1990: Hagop M Kantarjian; R L Walters; Michael J Keating; Elihu H Estey; Susan O'Brien; J Schachner; K B McCredie; Emil J Freireich
Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia.
Cancer 1990;65(1):5-8.
1990: Elihu H Estey; Hagop M Kantarjian; Miloslav Beran; K B McCredie; Michael J Keating; Albert Deisseroth; Jordan U Gutterman
Treatment of poor-prognosis, newly diagnosed acute myelogenous leukemia with high-dose cytosine arabinoside (Ara-C) and rHUGM-CSF.
Haematology and blood transfusion 1990;33():732-6.
1989: J D Cason; J M Trujillo; Elihu H Estey; Y O Huh; Emil J Freireich; Sanford A Stass
Peripheral acute leukemia: high peripheral but low-marrow blast count.
Blood 1989;74(5):1758-61.
1987: Elihu H Estey; Michael J Keating; K B McCredie; Emil J Freireich
Continuous-infusion amsacrine in patients with refractory acute myelogenous leukemia.
Cancer treatment reports 1987;71(11):1113-4.
1987: Elihu H Estey; Michael J Keating; D O Dixon; J M Trujillo; K B McCredie; Emil J Freireich
Karyotype is prognostically more important than the FAB system's distinction between myelodysplastic syndrome and acute myelogenous leukemia.
Hematologic pathology 1987;1(4):203-8.